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Synopsis  
 
Levels of GAS5 lncRNA, an apoptosis promoter and riborepressor of the androgen receptor, are 
down-regulated as prostate cancer cells acquire castrate-resistance, and consequently this molecule 
may offer new opportunities for the therapy of castrate-resistant prostate cancer. The mTOR 
pathway regulates GAS5 lncRNA levels, and here we have investigated using mTOR inhibitors to 
enhance GAS5 lncRNA in preclinical models of prostate cancer. mTOR inhibitors enhanced GAS5 
transcript levels in androgen-sensitive but not in androgen-independent cell lines, which exhibit 
especially low levels of endogenous GAS5 lncRNA. Indeed, in prostate cancer cells, GAS5 silencing 
induces resistance to, and ectopic GAS expression confers sensitivity to, the cytostatic effects of 
mTOR inhibitors, thereby demonstrating a role for GAS5 lncRNA in mTOR inhibitor action. 
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Abstract 
 
Background: New therapies are required for castrate-resistant prostate cancer (CRPC), and growth-
arrest specific 5 (GAS5) lncRNA, which riborepresses androgen receptor action, may offer novel 
opportunities in this regard. This lncRNA promotes the apoptosis of prostate cancer cells and its 
levels decline as prostate cancer cells acquire castrate-resistance, so that enhancing GAS5 
expression may improve the effectiveness of chemotherapies. Since GAS5 is a member of the 5’ 
terminal oligopyrimidine gene family, we have examined mTOR inhibition as a strategy to increase 
GAS5 expression. Furthermore, we have determined if GAS5 itself mediates the action of mTOR 
inhibitors, as demonstrated for other chemotherapeutic agents in prostate cancer cells. 
 Methods: The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in 
a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs 
was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. 
Results: First generation mTORC1, combined mTORC1/mTORC2 and dual PI3K/mTOR inhibitors all 
increased cellular GAS5 levels and inhibited culture growth in androgen-dependent (LNCaP) and 
androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU 145) cell lines. 
The latter exhibited low endogenous GAS5 expression, and GAS5 silencing in LNCaP and 22Rv1 cells 
decreased the sensitivity to mTOR inhibitors, whereas transfection of GAS5 lncRNA sensitized PC-3 
and DU 145 cells to these agents.  
Conclusion: mTOR inhibition enhances GAS5 transcript levels in certain prostate cancer cell lines. 
This selectivity is likely to be related to endogenous GAS5 expression levels, since GAS5 lncRNA is 
itself required for mTOR inhibitor action in prostate cancer cells.   
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     Introduction 
 
Prostate cancer (PCa)  is the second most common malignancy and a leading cause of cancer related 
mortality in men [1]. Androgen plays a pivotal role in prostate cell biology, with the normal balance 
between the proliferation and death of glandular epithelial cells being predominantly under the 
control of androgen [2, 3]. Thus prostate cells require androgen to promote cell survival and 
proliferation, whereas androgen deprivation induces apoptosis [4, 5]. Androgen deprivation therapy 
(ADT) is the mainstay for the treatment of advanced prostate cancer, however it is only palliative, as 
prolonged  ADT invariably gives way to castrate-resistant prostate cancer (CRPC) [6] i.e, persistent 
tumour growth despite castrate levels of serum testosterone [5, 7]. At the cellular level, the 
development of CRPC represents a major compensatory response to androgen deprivation-induced 
stress, allowing cancer cells to survive and subsequently thrive in a low testosterone environment 
[8].   
 
The majority of chemotherapies act via the induction of apoptosis and, currently, there is a critical 
need to develop new treatments for CRPC, since apoptotic evasion is a key feature of this disease [5, 
9, 10].  In this regard, long non-coding RNAs (lncRNAs) may offer new drug targets, as they are 
increasingly recognised as key regulators of cellular processes and are recognised as of importance 
in the pathogenesis of many cancers including that of PCa [11-14]. 
 
The lncRNA and small nucleolar RNA (snoRNA) host gene, growth arrest-specific 5 (GAS5), is encoded 
at a prostate cancer-associated locus, 1q25 [15]. The gene was identified via subtractive cDNA 
cloning for potential novel tumour suppressor genes associated with growth-arrested cells [16].  
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GAS5 comprises 12 exons which encode two mature lncRNAs [16], while ten box C/D snoRNA are 
encoded within introns [17]; three of these snoRNAs (U44, U74 and U78) may also give rise to 
miRNAs [18]. GAS5 is a member of the 5’-terminal oligopyrimidine tract (5’-TOP) gene family [10, 16, 
18]. GAS5 transcripts accumulate in growth arrested cells [14], due to interplay between two 
pathways [16, 18]. Firstly, the mTOR pathway, through its regulation of translation of RNAs carrying 
the 5’-TOP sequence and, secondly, nonsense mediated decay (NMD, which degrades transcripts 
containing stop codons in early exons), due to the short GAS5 reading frame which terminates with a 
stop codon within exon 3 (of 12) [16, 19]. Thus, in actively growing cells, where mTOR activity is high, 
translation of the short reading frame is promoted, and degradation of transcripts by the NMD 
pathway results in low cellular GAS5 levels. Suppression of mTOR activity, such as occurs upon 
growth arrest, prevents active translation of GAS5 transcripts and their consequent degradation by 
NMD, resulting in the accumulation of GAS5 transcripts [20, 21].  
 
GAS5 is of a particular interest in CRPC, as its levels are down-regulated in LNCaP xenografts upon 
the acquisition of castrate-resistance [22]. This is of significance, as a portion of GAS5 sequence 
mimics the glucocorticoid receptor response element (GRE) and  riborepresses glucocorticoid 
receptor action [23]. More importantly, in the prostate context, GAS5 lncRNA also sequesters the 
androgen/androgen receptor complex and prevents its binding to target DNA sequences [24].  
Moreover, functional studies have shown that GAS5 lncRNA promotes the apoptosis of prostate 
cancer cells [10] , and  have demonstrated a quantitative relationship between the extent of cell 
death and cellular GAS5 lncRNA  levels [10]. Enhancement of cellular GAS5 lncRNA levels in 
combination with chemotherapeutic drugs may therefore offer an improved strategy for the 
treatment of advanced PCa. 
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One way to enhance cellular GAS5 lncRNA levels in prostate cancer cells may be through mTOR 
inhibition, as previously demonstrated for lymphoid and certain breast cancer cell lines [20, 21].  
Indeed, there is currently much interest in the clinical use of mTOR inhibitors, either alone or in 
combination with other therapies, for the treatment of PCa, particularly since activation of the 
PI3K/Akt/mTOR pathway has been implicated in prostate cancer progression and the development 
of drug and radiation resistance.  Here we have investigated the efficacy of various classes of mTOR 
inhibitors, comprising allosteric mTORC1, combined mTORC1/mTORC2 and dual PI3K/mTOR 
inhibitors, in enhancing GAS5 lncRNA levels in a range of prostate cancer cell lines. In addition, we 
have also examined whether GAS5 lncRNA is itself required for mTOR inhibitor action in prostate 
cancer cells [10], as has been previously shown for lymphoid cells [20], since this may impact upon 
the clinical effectiveness of such agents in suppressing cancer growth through the induction of cell 
cycle arrest and apoptosis.  
 
Materials and Methods 
 
Materials 
The prostate cancer cell lines 22Rv1, LNCaP, PC-3 and DU 145 were from ATCC-LGC Promochem 
(Teddington, UK); PNT2C2 cells were obtained from Prof N. J Maitland (University of York, 
Heslington, UK). Cell culture materials and classical chemotherapeutic drugs were from Sigma-
Aldrich Company Ltd (Gillingham, UK). Sources of other drugs were: rapamycin (Millipore, Watford, 
UK), everolimus and temsirolimus (LC Laboratories, Woburn, MA), BEZ235 and AZD8055 (Stratech 
Scientific, Newmarket, UK). TRIsure and Silencer Select siRNAs were from Life Technologies Ltd 
(Paisley, UK). RNase-free DNase, reverse transcriptase and CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay was from Promega (Southampton, UK). Brilliant III SYBR Green was from 
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Stratagene (Santa Clara, CA). HiPerFect transfection reagent was from Qiagen (Crawley, UK) and 
nucleofector solutions were from Lonza Biosciences (Verviers, Belgium). 
Cell Culture 
LNCaP, PNT2C2 and 22Rv1 were routinely cultured in RPMI-1640, supplemented with 2 mM  L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum and 50 µg/mL 
gentamicin. Culture medium for PC-3 was nutrient mix F-12 (Kaighn’s modification) supplemented 
with 10% fetal bovine serum and 50 µg/mL gentamicin (Sigma). Culture medium for DU 145 was 
Eagles minimum essential medium (EMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate and 50 µg/mL gentamicin.   All cell lines were cultured at 37 °C in 
a humidified incubator with 5% CO2. 
 
Plasmid DNA Transfection 
Plasmids were pcDNA3/GAS5.AE (encodes mature GAS5 lncRNA) and pcDNA3 vector (control), as 
previously described [3, 21]. In brief, PC-3 and DU 145 cells were nucleofected with plasmids (2 µg 
per 2 X 10
6
 cells in 0.1 ml nucleofector solution V and L, respectively) using programmes T-013 and 
A-023, respectively, and cells were then cultured in 3 ml of the appropriate culture medium in 6-well 
plates for 24 h before use. 
 
RNA interference by siRNA 
Trypsinized 22Rv1 and LNCaP cells were plated in 6-well plates (2 X 10
5
/well). At 30 min post-plating, 
cells were transfected with Ambion Silencer Select siRNAs to GAS5 using HiPerFect reagent and a 
fast-forward protocol, according to the manufacturer’s instructions; the final siRNA concentration 
was 186 nM. Two different siRNAs were employed for GAS5 knockdown, termed GAS5#3 and #4, as 
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previously described [10]. Controls were transfected with negative control (NC) siRNA. Transfection 
efficiencies, determined in parallel transfections with Cy3-labelled NC siRNA, were 97 ± 3% for 22Rv1 
and 90 ± 5% for LNCaP at 48 h post transfection. Cells were cultured for 24 h post-transfection 
before further experimentation.  
 
Assessment of mTOR inhibitor sensitivity. 
At 24 h post transfection, cells were plated in 96-well plates (500 cells in 0.1 ml medium) and also 6-
well plates (2 X 10
5
 cells in 2 ml medium) and incubated overnight. An equal volume of medium 
containing the appropriate drug or vehicle (final concentrations: 1 µM rapamycin, 10 nM everolimus, 
10 nM temsirolimus, 100 nM BEZ235, 50 nM AZD8055 or 0.1% DMSO) was then added [21]. Cells 
were harvested at 24 h (6-well plates: for GAS5 determination) or at 72 h (96-well plates: for MTS 
assay).   
 
Culture Proliferation assay 
Growth was assessed by a tetrazolium salt (MTS) assay or by direct microscopic counting. The MTS 
assay comprised CellTiter 96 Aqueous One Solution Cell Proliferation Assay, which was used in 
accordance to the manufacturer’s instructions and as previously described [10, 21]. Medium blanks 
containing the drugs under test were run with each assay and the absorbance readings at 490 nm 
(A490) were subtracted from the appropriate test readings. For direct microscopic counting, adherent 
cells were collected by trypsinisation, stained with 0.1% [w/v] nigrosin blue, and counted using a 
hemocytometer; cells that excluded the dye were considered to be viable. 
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Clonogenic Growth Assay 
Long-term survival of cells was determined by a colony forming assay. Cells were washed 48 h post 
drug treatment in sterile PBS and re-suspended in fresh medium supplemented with 10% cell-
conditioned medium (1 mL/cm
2
 culture area), and proportions (usually 2.5-10.0 µl cells) were plated 
into 6-well culture plates in 2.5 mL final culture volume. After 2-4 weeks, cells were stained with 
crystal violet (0.1% (w/v) in methanol) and the number of colonies (comprising ≥10 cells) were 
counted.  
 
Quantitative RT-PCR 
Total RNA was extracted from cells, as previously described [10, 25, 26]. RNA was DNAse treated 
prior to cDNA synthesis. cDNA was synthesized using 200 U of Moloney mouse leukaemia virus 
reverse transcriptase using Random hexame  Primer (Promega) according to the manufacturer’s 
instructions and as previously described [25, 27]. 
 
The primer sequences used for GAS5 quantification were: forward 5’-CCTGGACCAGCTTAATGGTT-3’ 
and reverse 5’-GTCTGCCTGCATTTCTTCAA-3’ (product size 190 bp). Briefly, reactions 12 µl final 
volume) contained 1X Brilliant SYBR green QPCR mastermix, 400 nmol  each of forward and reverse 
primers and 10 ng sample cDNA. All samples were analysed in triplicate [25, 26]. The target genes 
were normalised to endogenous controls GAPDH and or 18S rRNA, and relative quantification was 
carried out using the 2
-ΔΔCT
 method, where: -ΔΔCT = cycle threshold (CT), 
(GAS5 of cell line-GAPDH cell line)-(GAS5 of 
vehicle-GAPDH of vehicle)
. Data are expressed relative to vehicle treated controls. 
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Statistical Analyses 
All experiments were repeated at least three times with triplicate determinations in each set of 
experiments. Data are presented as the mean ± SEM; the number of observations (n) refers to 
number of different experiments, each derived from a separate culture. Data analysis was carried 
out by one-way ANOVA with Dunnett’s multiple comparison post-test or Bonferroni’s multiple 
comparison test using GraphPad Prism. 
 
Results 
Endogenous GAS5 expression 
A range of established, well characterized prostate cell lines were studied, comprising: PNT2C2, 
derived by immortalisation of normal prostate cells [31]; 22Rv1, an androgen-sensitive cell line 
derived from a prostate cancer xenograft [32]; LNCaP, an androgen-dependent cell line derived from 
a supraclavicular lymph node metastasis of prostate cancer [33]; PC-3, an androgen-independent cell 
line derived from a bone metastases of prostate cancer [34] and DU 145, an androgen independent 
cell line derived from a brain metastasis of prostate cancer [35]. 
 
Previous work has shown that GAS5 levels are reduced in prostate cancer cell lines representative of 
advanced disease, relative to immortalized prostate cells [22]. Indeed measurement of GAS5 lncRNA 
levels in actively growing cells in the present study confirmed these findings. Thus, relative to 
PNT2C2 cells, values were similar in 22Rv1 cells but markedly lower in LNCaP, DU 145 and PC-3 cells 
(Fig. 1). Among the latter group of cell lines, which are all derived from prostate metastases, levels 
were significantly lower in PC-3 cells compared with LNCaP cells, whereas DU 145 cells exhibited 
intermediate levels of expression (Fig. 1).  
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Rapamycin and rapalogues selectively modulate GAS5 expression and culture growth in prostate 
cell lines 
The effectiveness of mTOR inhibitors to enhance cellular GAS5 lncRNA levels in a range of prostate 
cell lines was examined, since GAS5 promotes the death of prostate cancer cells [10]. The first 
generation mTOR inhibitors rapamycin, everolimus and temsirolimus were chosen initially for this 
study [28-30]. 
 
In general, first generation mTOR inhibitors markedly enhanced GAS5 expression and slightly 
inhibited the growth of PNT2C2 cells (Fig. 2A). In the prostate cancer cell lines 22Rv1 (Fig. 2B ) and 
LNCaP (Fig. 2C ) cellular GAS5 levels were enhanced by all agents to a similar extent as for PNT2C2 
cells, but more potent inhibition of culture growth and clonogenic activity was seen. In contrast, PC-
3 and DU 145 cells, were characterized by resistance to all inhibitors, in terms of GAS5 cellular levels, 
short-term culture growth and clonogenic activity (Fig. 2D and 2E).  
 
Second generation mTOR inhibitors selectively modulate GAS5 expression and growth in prostate 
cell lines 
The mTOR inhibitors are in increasing clinical use, and resistance to such agents, especially first 
generation inhibitors which act selectively on mTORC1, is becoming progressively evident.  This has 
prompted the development of inhibitors with broader specificity, i.e the dual mTORC1/mTORC2 
inhibitor, AZD8055, and the combined PI3K/mTOR inhibitor, BEZ235. In related work, we have 
observed that these newer generation inhibitors can effectively enhance cellular GAS5 levels in 
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breast cancer cells which otherwise show resistance to selective mTORC1 inhibitors [21]. For these 
reasons, we examined the effects of such agents on prostate cell lines.   
 
However, the pattern of cell line response to both AZD8055 and BEZ235 was similar to that of the 
rapalogues, insofar as these two drugs elevated GAS5 expression and inhibited growth/clonogenic 
activity in PNT2C2 (Fig. 3A), 22Rv1 (Fig. 3B) and LNCaP cells (Fig. 3C) only, whereas the PC-3 and DU 
145 cell lines showed no increase in GAS5 levels accompanied by complete resistance to these 
agents (Fig. 3D and 3E). 
 
GAS5 silencing attenuates mTOR inhibitor action in prostate cancer cells. 
GAS5 lncRNA has been previously shown to be required for mTOR inhibitor action in a range of 
lymphoid cell lines [31], and a similar relationship may account for the reduced sensitivity of PC-3 
and DU 145 cells to mTOR inhibitors, particularly since GAS5 levels are low in these cell lines. To test 
the postulate that GAS5 lncRNA is required for mTOR inhibitor action in prostate cancer cells, we 
initially examined the effect of GAS5 silencing on mTOR inhibitor action in the two sensitive cell 
lines, 22Rv1 and LNCaP, which exhibit relatively high and low steady state levels of GAS5 lncRNA, 
respectively (Fig. 4 and 5).  Two different GAS5 siRNAs were employed in these experiments to 
reduce the likelihood of ‘off-target’ effects.  
 
In 22Rv1 cells, GAS5 transcript levels were reduced by ca. 80% in cells treated with each GAS5 siRNA 
(Fig. 4A). This was accompanied by a small (ca. 30%) reduction in culture growth (Fig. 4B). Rapalogue 
treatment produced the expected growth inhibition in mock-transfected cells (Fig. 4C) and in cells 
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transfected with negative control siRNA cells (Fig. 4D), whereas prior GAS5 silencing, markedly and 
consistently attenuated such growth inhibition (Figs. 4E and 4F).   
 
The two GAS5 siRNAs also markedly reduced GAS5 expression in LNCaP cells (Fig. 5A), albeit this was 
without any effect on culture growth (Fig. 5B). In agreement with findings in 22Rv1 cells, rapalogues 
markedly inhibited the growth of control LNCaP cells (Figs. 5C and 5D) but had little effect on cells in 
which GAS5 expression had been silenced (Figs. 5E and 5F). Taken together, these findings support 
the hypothesis that GAS5 lncRNA is required for the growth inhibitory activity of rapalogues in 
prostate cancer cells. 
 
GAS5 lncRNA sensitizes PC-3 and DU 145 cells to mTOR inhibitors 
We next examined if prior transfection with GAS5 lncRNA could influence the sensitivity of PC-3 and 
DU 145 cells to both first generation and second generation mTOR inhibitors (Figs. 6 and 7). 
Nucleofection of the GAS5 plasmid construct enhanced cellular GAS5 levels three-fold in both PC-3 
(Fig. 6A) and DU 145 cells (Fig. 7A) and this was without effect on the overall rate of culture growth 
(Figs. 6B and 7B). Both mock- and vector-transfected controls exhibited complete insensitivity to all 
mTOR inhibitors in terms of their culture growth (Figs. 6C, 6D, 7C and 7D), as expected, whereas cells 
transfected with the GAS5 lncRNA exhibited marked inhibition of culture growth upon rapalogue 
treatment (Figs. 6E and 7E).  These findings therefore suggest that a minimum level of GAS5 lncRNA 
is required for the cytostatic/cytotoxic action of mTOR inhibitors on prostate cancer cells. 
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Discussion 
 
A major problem with current, first line androgen deprivation therapy for prostate cancer is the 
development of CRPC, which ultimately proves lethal [28]. Thus there is an urgent need to develop 
new therapies for CRPC and GAS5 lncRNA may offer new opportunities in this regard, since the 
survival of prostate cancer cells upon challenge with chemotherapeutic agents and other inducers of 
apoptosis has been shown to inversely correlate with cellular GAS5 lncRNA levels [10]. Here we have 
investigated mTOR inhibition as a strategy to enhance GAS5 levels in prostate cancer cells, and we 
demonstrate that such agents are effective in androgen-dependent/sensitive cell lines (22Rv1 and 
LNCaP) but not in androgen-independent cell lines (PC-3 and DU 145). The latter cells are 
characterized by relatively low levels of endogenous GAS5 lncRNA, and we further demonstrate that 
GAS5 lncRNA is itself required for mTOR inhibitor action in prostate cancer cells, thereby providing 
an explanation for the resistance of androgen-independent cells to mTOR inhibition. Moreover, 
these findings have important implications for prostate cancer therapies involving mTOR inhibitors.  
 
Currently there is much interest in the use of mTOR inhibitors as novel therapies in prostate cancer, 
and mTOR inhibitors would therefore appear an attractive pharmacological option to enhance 
cellular GAS5 lncRNA levels [16, 32]. First and second generation mTOR inhibitors exerted robust 
effects on both androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) prostate cancer cell 
lines, whereas androgen-independent PC-3 and DU 145 cells failed to respond to these agents (at 
the concentrations studied here), both in terms of GAS5 expression and culture growth. Similar 
findings have been reported for breast cancer cell lines, insofar as growth and GAS5 expression in 
hormone-independent cells show greater resistance to mTORC1 and combined mTORC1/mTORC2 
inhibition than hormone-sensitive cells [21]. Thus using mTOR inhibitors to elevate GAS5 levels in 
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prostate cancer cells in order to promote their death  is unlikely to succeed in CRPC, but it may be 
successful in less advanced disease.  Alternative approaches are therefore required to elevate GAS5 
expression levels in CRPC. 
 
Studies in lymphoid cells have shown that GAS5 lncRNA is required for rapalogue action, but this 
issue has not been previously addressed in prostate cells or any other epithelial cell type [20]. Since 
endogenous GAS5 lncRNA levels are shown to be lower in prostate cancer cell lines derived from 
metastases than in immortalized prostate cells, in confirmation of previous findings [[22], we 
postulated that a similar relationship may account for mTOR sensitivity in prostate cells. Here we 
demonstrate that prior GAS5 silencing induces mTOR inhibitor-insensitivity (both in terms of GAS5 
lncRNA expression and culture growth) in the otherwise mTOR-sensitive cell lines, 22Rv1 and LNCaP, 
thereby demonstrating a requirement for GAS5 lncRNA for rapalogue action. Moreover, upon 
transfection with GAS5 lncRNA, PC-3 and DU 145 cells acquire rapalogue sensitivity, further 
demonstrating that GAS5 lncRNA modulates mTOR inhibitor action.  Thus decreased GAS5 
expression in prostate cancer cells, such as occurs upon the acquisition of castrate-resistance, not 
only has the potential to attenuate the action of classical chemotherapeutic drugs [10], but also that 
of more novel targeted therapies, such as mTOR inhibitors. Better understanding of the mechanisms 
underlying reduced expression of GAS5 lncRNA upon the acquisition of castrate resistance is 
required, as this will help identify potential alternative means to enhance cellular GAS5 expression. 
Currently we are investigating epigenetic mechanisms in this respect, as well as the involvement of 
the recently discovered  GAS5 antisense RNA 1 (GAS5-AS1) gene.   
 
Current findings have broader implications for the use of mTOR inhibitors in prostate cancer. The 
oncogenic PI3K/Akt/mTOR signalling pathway plays a key role in the development and maintenance 
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of prostate cancer and is deregulated in the majority of advanced prostate cancers [20]. In 
particular, the pathway serves as a critical nexus for the integration of growth signals with 
downstream cellular processes so that its activation such as occurs in prostate cancer [7-9] provides 
mechanisms for cancer cells to overcome the stress associated with, for example, androgen 
deprivation [5, 33]. These considerations have prompted the active investigation of mTOR inhibitors, 
either as single agents or in combination with other agents, as a novel targeted therapy for advanced 
prostate cancer, and the clinical effectiveness of single agent, first-generation mTOR inhibitors, such 
as everolimus and temsirolimus, has so far been disappointing.  Our data, demonstrating an 
association between low GAS5 levels and increased resistance to the growth inhibitory effects of 
rapalogues in a model of androgen-independent disease, coupled with the direct demonstration that 
GAS5 lncRNA modulates mTOR inhibitor action in advanced prostate cancer cells, raises the 
possibility that low GAS5 expression in advanced prostate cancer may contribute to the clinical 
ineffectiveness of rapalogues in this disease. Current findings may also have broader implications for 
the clinical use of mTOR inhibitor-based therapies in a wide range of other cancers, including head 
and neck squamous cell carcinoma [34], glioblastoma multiforme [35], renal clear cell carcinoma 
[36], bladder cancer [37], pancreatic cancer [38] and non-small cell lung cancer [39], all of which are 
characterised by deficient GAS5 expression.  
Conclusions 
Cellular GAS5 expression can be enhanced by the use of mTORC1/mTOR inhibitors in androgen-
dependent/sensitive prostate cancer cells but not in androgen-independent cells. The refractoriness 
of the latter cells may in part be due to their low levels of endogenous GAS5 lncRNA expression, 
since GAS5 lncRNA positively regulates mTOR inhibitor action. Additional approaches are therefore 
required to increase GAS5 lncRNA expression in advanced prostate cancers in order to promote the 
effectiveness of chemotherapeutic agents and ultimately to improve and enhance patient outcomes.  
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Figure Legends 
 
Figure 1. Endogenous levels of GAS5 lncRNA in prostate cell lines. Endogenous GAS5 lncRNA levels 
were determined in actively growing prostate cell lines by RT-qPCR. Data are expressed as a 
percentage relative to PNT2C2 cells using ΔCT analysis, using GAPDH for normalization. Each bar 
represents the mean ± SEM for three independent experiments. Data were analysed by one-way 
ANOVA with Bonferroni’s multiple comparison test. #, P < 0.001 vs PNT2C2, *, P < 0.001 vs 22Rv1, ^, 
P < 0.001 vs LNCaP, -, P < 0.05 vs DU 145. 
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Figure 2. Effects of pharmacological inhibitors of mTORC1 activity on GAS5 expression, culture 
growth and the survival of prostate cell lines.  Effects of rapamycin 1 µM (R), everolimus 10 nM (E) 
and temsirolimus 10 nM (T) on GAS5 expression (24h; left-hand panel), culture growth (72 h; middle 
panel) and clonogenic survival (right-hand panel) in: A PNT2C2 cells B 22Rv1 cells, C LNCaP cells, D 
PC-3 cells and E DU 145 cells. Results are expressed as a proportion of the respective vehicle-treated 
controls. Each bar represents the mean ± SEM from three independent experiments. Data were 
analysed by one-way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05; **, P < 0.01 
and ***,  P < 0.001 versus vehicle.  
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Figure 3. Effects of combined mTORC1/mTORC2 and dual mTOR/PI3K inhibitors on GAS5 
expression, culture growth and the survival of prostate cell lines.  Effects of AZD8055 (50 nM) and 
BEZ235 (100 nM) on GAS5 expression (24h; left-hand panel), culture growth (72h; middle panel) and 
clonogenic survival (right-hand panel) in: A PNT2C2 cells, B 22Rv1 cells, C LNCaP cells, D PC-3 cells 
and E DU 145 Cells. Results are expressed as a proportion of the respective vehicle-treated controls. 
Each bar represents the mean ± SEM from three independent experiments. Data were analysed by 
one-way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05; **, P < 0.01 and ***,  P < 
0.001 versus vehicle.  
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Figure 4. Effect of GAS5 silencing on mTOR inhibitor action in 22Rv1 cells. 22Rv1 cells were 
transfected with the indicated GAS5 siRNA (GAS5#3 or GAS5#4), negative control (NC) siRNA or 
mock-transfected and, after 48 h, samples were collected for determination of GAS5 lncRNA levels 
and cells were exposed to rapalogues (rapamycin 1 µM (R), everolimus 10 nM (E) and temsirolimus 
10 nM (T)) for 72 h. A GAS5 lncRNA levels; data are expressed relative to  mock-transfected cells. B 
MTS assay results comparing the absolute growth of vehicle-treated, transfected cells. C-F MTS assay 
of the effect of rapalogues on the growth of transfected cells; data are expressed relative to 
respective vehicle (V)-treated controls for: C mock-transfected cells, D NC transfected cells, E 
GAS5#3 transfected cells and F GAS5#4 transfected cells. Each bar represents the mean value ± SEM 
from three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. *, P < 0.05 and ***, P < 0.001 versus the respective 
vehicle-treated control. 
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Figure 5. Effect of GAS5 silencing on mTOR inhibitor action in LNCaP cells.  
LNCaP cells were transfected with the indicated GAS5 siRNA (GAS5#3 or GAS5#4), negative control 
(NC) siRNA or mock-transfected and, after 48 h, samples were collected for determination of GAS5 
lncRNA levels and cells were exposed to rapalogues (rapamycin 1 µM (R), everolimus 10 nM (E) and 
temsirolimus 10 nM (T)) for 72 h. A GAS5 lncRNA levels; data are expressed relative to mock-
transfected cells. B MTS assay results comparing the absolute growth of vehicle-treated, transfected 
cells. C-F MTS assay of the effect of rapalogues on the growth of transfected cells; data are 
expressed relative to respective vehicle (V)-treated controls for: C mock-transfected cells, D NC 
transfected cells, E GAS5#3 transfected cells and F GAS5#4 transfected cells. Each bar represents the 
mean value ± SEM from three independent experiments. Data were analysed for significance by one-
way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05 and ***, P < 0.001 versus the 
respective vehicle-treated control. 
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Figure 6. Effect of GAS5 lncRNA on mTOR inhibitor action in PC-3 cells.  
PC-3 cells were transfected with plasmids corresponding to mature lncRNA (pcDNA3+GAS5) or 
empty vector (pcDNA3), or mock-transfected. At 24 h, samples were taken for determination of 
GAS5 lncRNA levels, and cells were treated with mTOR inhibitors (rapamycin [1 µM; R]; everolimus 
[10 nM; E]; temsirolimus [10 nM; T]; AZD8055 [50 nM; AZD]; and BEZ235 [100 nM; BEZ]) for 72h. A 
GAS5 lncRNA levels; data are relative to mock-transfected cells. B MTS assay results comparing the 
absolute growth of vehicle-treated, transfected cells only. C-E MTS assay results for mTOR inhibitor-
treated cells; data are expressed relative to vehicle-treated cells for: C mock-transfected cells, D 
vector-transfected cells, E GAS5 lncRNA-transfected cells. Each bar represents the mean value ± SEM 
from three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. ***, P < 0.001 versus vehicle control. 
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Figure 7. Effect of GAS5 lncRNA on mTOR inhibitor action in DU 145 cells. DU 145 cells were 
transfected with plasmids corresponding to mature lncRNA (pcDNA3+GAS5) or empty vector 
(pcDNA3), or mock-transfected. At 24 h, samples were taken for determination of GAS5 lncRNA 
levels, and cells were treated with mTOR inhibitors (rapamycin [1 µM; R]; everolimus [10 nM; E]; 
temsirolimus [10 nM; T]; AZD8055 [50 nM; AZD]; and BEZ235 [100 nM; BEZ]) for 72h. A GAS5 lncRNA 
levels; data are relative to mock-transfected cells. B MTS assay results comparing the absolute 
growth of vehicle-treated, transfected cells only. C-E MTS assay results for mTOR inhibitor-treated 
cells; data are expressed relative to vehicle-treated cells for: C mock-transfected cells, D vector-
transfected cells, E GAS5 lncRNA-transfected cells. Each bar represents the mean value ± SEM from 
three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. . ***, P < 0.001 versus vehicle control. 
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Synopsis  
 
Levels of GAS5 lncRNA, an apoptosis promoter and riborepressor of the androgen receptor, are 
down-regulated as prostate cancer cells acquire castrate-resistance, and consequently this molecule 
may offer new opportunities for the therapy of castrate-resistant prostate cancer. The mTOR 
pathway regulates GAS5 lncRNA levels, and here we have investigated using mTOR inhibitors to 
enhance GAS5 lncRNA in preclinical models of prostate cancer. mTOR inhibitors enhanced GAS5 
transcript levels in androgen-sensitive but not in androgen-independent cell lines, which exhibit 
especially low levels of endogenous GAS5 lncRNA. Indeed, in prostate cancer cells, GAS5 silencing 
induces resistance to, and ectopic GAS expression confers sensitivity to, the cytostatic effects of 
mTOR inhibitors, thereby demonstrating a role for GAS5 lncRNA in mTOR inhibitor action. 
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Abstract 
 
Background: New therapies are required for castrate-resistant prostate cancer (CRPC), and growth-
arrest specific 5 (GAS5) lncRNA, which riborepresses androgen receptor action, may offer novel 
opportunities in this regard. This lncRNA promotes the apoptosis of prostate cancer cells and its 
levels decline as prostate cancer cells acquire castrate-resistance, so that enhancing GAS5 
expression may improve the effectiveness of chemotherapies. Since GAS5 is a member of the 5’ 
terminal oligopyrimidine gene family, we have examined mTOR inhibition as a strategy to increase 
GAS5 expression. Furthermore, we have determined if GAS5 itself mediates the action of mTOR 
inhibitors, as demonstrated for other chemotherapeutic agents in prostate cancer cells. 
 Methods: The effects of mTOR inhibitors on GAS5 lncRNA levels and cell growth were determined in 
a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNAs and plasmid constructs 
was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action. 
Results: First generation mTORC1, combined mTORC1/mTORC2 and dual PI3K/mTOR inhibitors all 
increased cellular GAS5 levels and inhibited culture growth in androgen-dependent (LNCaP) and 
androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU 145) cell lines. 
The latter exhibited low endogenous GAS5 expression, and GAS5 silencing in LNCaP and 22Rv1 cells 
decreased the sensitivity to mTOR inhibitors, whereas transfection of GAS5 lncRNA sensitized PC-3 
and DU 145 cells to these agents.  
Conclusion: mTOR inhibition enhances GAS5 transcript levels in certain prostate cancer cell lines. 
This selectivity is likely to be related to endogenous GAS5 expression levels, since GAS5 lncRNA is 
itself required for mTOR inhibitor action in prostate cancer cells.   
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     Introduction 
 
Prostate cancer (PCa)  is the second most common malignancy and a leading cause of cancer related 
mortality in men [1]. Androgen plays a pivotal role in prostate cell biology, with the normal balance 
between the proliferation and death of glandular epithelial cells being predominantly under the 
control of androgen [2, 3]. Thus prostate cells require androgen to promote cell survival and 
proliferation, whereas androgen deprivation induces apoptosis [4, 5]. Androgen deprivation therapy 
(ADT) is the mainstay for the treatment of advanced prostate cancer, however it is only palliative, as 
prolonged  ADT invariably gives way to castrate-resistant prostate cancer (CRPC) [6] i.e, persistent 
tumour growth despite castrate levels of serum testosterone [5, 7]. At the cellular level, the 
development of CRPC represents a major compensatory response to androgen deprivation-induced 
stress, allowing cancer cells to survive and subsequently thrive in a low testosterone environment 
[8].   
 
The majority of chemotherapies act via the induction of apoptosis and, currently, there is a critical 
need to develop new treatments for CRPC, since apoptotic evasion is a key feature of this disease [5, 
9, 10].  In this regard, long non-coding RNAs (lncRNAs) may offer new drug targets, as they are 
increasingly recognised as key regulators of cellular processes and are recognised as of importance 
in the pathogenesis of many cancers including that of PCa [11-14]. 
 
The lncRNA and small nucleolar RNA (snoRNA) host gene, growth arrest-specific 5 (GAS5), is encoded 
at a prostate cancer-associated locus, 1q25 [15]. The gene was identified via subtractive cDNA 
cloning for potential novel tumour suppressor genes associated with growth-arrested cells [16].  
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GAS5 comprises 12 exons which encode two mature lncRNAs [16], while ten box C/D snoRNA are 
encoded within introns [17]; three of these snoRNAs (U44, U74 and U78) may also give rise to 
miRNAs [18]. GAS5 is a member of the 5’-terminal oligopyrimidine tract (5’-TOP) gene family [10, 16, 
18]. GAS5 transcripts accumulate in growth arrested cells [14], due to interplay between two 
pathways [16, 18]. Firstly, the mTOR pathway, through its regulation of translation of RNAs carrying 
the 5’-TOP sequence and, secondly, nonsense mediated decay (NMD, which degrades transcripts 
containing stop codons in early exons), due to the short GAS5 reading frame which terminates with a 
stop codon within exon 3 (of 12) [16, 19]. Thus, in actively growing cells, where mTOR activity is high, 
translation of the short reading frame is promoted, and degradation of transcripts by the NMD 
pathway results in low cellular GAS5 levels. Suppression of mTOR activity, such as occurs upon 
growth arrest, prevents active translation of GAS5 transcripts and their consequent degradation by 
NMD, resulting in the accumulation of GAS5 transcripts [20, 21].  
 
GAS5 is of a particular interest in CRPC, as its levels are down-regulated in LNCaP xenografts upon 
the acquisition of castrate-resistance [22]. This is of significance, as a portion of GAS5 sequence 
mimics the glucocorticoid receptor response element (GRE) and  riborepresses glucocorticoid 
receptor action [23]. More importantly, in the prostate context, GAS5 lncRNA also sequesters the 
androgen/androgen receptor complex and prevents its binding to target DNA sequences [24].  
Moreover, functional studies have shown that GAS5 lncRNA promotes the apoptosis of prostate 
cancer cells [10] , and  have demonstrated a quantitative relationship between the extent of cell 
death and cellular GAS5 lncRNA  levels [10]. Enhancement of cellular GAS5 lncRNA levels in 
combination with chemotherapeutic drugs may therefore offer an improved strategy for the 
treatment of advanced PCa. 
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One way to enhance cellular GAS5 lncRNA levels in prostate cancer cells may be through mTOR 
inhibition, as previously demonstrated for lymphoid and certain breast cancer cell lines [20, 21].  
Indeed, there is currently much interest in the clinical use of mTOR inhibitors, either alone or in 
combination with other therapies, for the treatment of PCa, particularly since activation of the 
PI3K/Akt/mTOR pathway has been implicated in prostate cancer progression and the development 
of drug and radiation resistance.  Here we have investigated the efficacy of various classes of mTOR 
inhibitors, comprising allosteric mTORC1, combined mTORC1/mTORC2 and dual PI3K/mTOR 
inhibitors, in enhancing GAS5 lncRNA levels in a range of prostate cancer cell lines. In addition, we 
have also examined whether GAS5 lncRNA is itself required for mTOR inhibitor action in prostate 
cancer cells [10], as has been previously shown for lymphoid cells [20], since this may impact upon 
the clinical effectiveness of such agents in suppressing cancer growth through the induction of cell 
cycle arrest and apoptosis.  
 
Materials and Methods 
 
Materials 
The prostate cancer cell lines 22Rv1, LNCaP, PC-3 and DU 145 were from ATCC-LGC Promochem 
(Teddington, UK); PNT2C2 cells were obtained from Prof N. J Maitland (University of York, 
Heslington, UK). Cell culture materials and classical chemotherapeutic drugs were from Sigma-
Aldrich Company Ltd (Gillingham, UK). Sources of other drugs were: rapamycin (Millipore, Watford, 
UK), everolimus and temsirolimus (LC Laboratories, Woburn, MA), BEZ235 and AZD8055 (Stratech 
Scientific, Newmarket, UK). TRIsure and Silencer Select siRNAs were from Life Technologies Ltd 
(Paisley, UK). RNase-free DNase, reverse transcriptase and CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay was from Promega (Southampton, UK). Brilliant III SYBR Green was from 
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Stratagene (Santa Clara, CA). HiPerFect transfection reagent was from Qiagen (Crawley, UK) and 
nucleofector solutions were from Lonza Biosciences (Verviers, Belgium). 
Cell Culture 
LNCaP, PNT2C2 and 22Rv1 were routinely cultured in RPMI-1640, supplemented with 2 mM  L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum and 50 µg/mL 
gentamicin. Culture medium for PC-3 was nutrient mix F-12 (Kaighn’s modification) supplemented 
with 10% fetal bovine serum and 50 µg/mL gentamicin (Sigma). Culture medium for DU 145 was 
Eagles minimum essential medium (EMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate and 50 µg/mL gentamicin.   All cell lines were cultured at 37 °C in 
a humidified incubator with 5% CO2. 
 
Plasmid DNA Transfection 
Plasmids were pcDNA3/GAS5.AE (encodes mature GAS5 lncRNA) and pcDNA3 vector (control), as 
previously described [3, 21]. In brief, PC-3 and DU 145 cells were nucleofected with plasmids (2 µg 
per 2 X 10
6
 cells in 0.1 ml nucleofector solution V and L, respectively) using programmes T-013 and 
A-023, respectively, and cells were then cultured in 3 ml of the appropriate culture medium in 6-well 
plates for 24 h before use. 
 
RNA interference by siRNA 
Trypsinized 22Rv1 and LNCaP cells were plated in 6-well plates (2 X 10
5
/well). At 30 min post-plating, 
cells were transfected with Ambion Silencer Select siRNAs to GAS5 using HiPerFect reagent and a 
fast-forward protocol, according to the manufacturer’s instructions; the final siRNA concentration 
was 186 nM. Two different siRNAs were employed for GAS5 knockdown, termed GAS5#3 and #4, as 
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previously described [10]. Controls were transfected with negative control (NC) siRNA. Transfection 
efficiencies, determined in parallel transfections with Cy3-labelled NC siRNA, were 97 ± 3% for 22Rv1 
and 90 ± 5% for LNCaP at 48 h post transfection. Cells were cultured for 24 h post-transfection 
before further experimentation.  
 
Assessment of mTOR inhibitor sensitivity. 
At 24 h post transfection, cells were plated in 96-well plates (500 cells in 0.1 ml medium) and also 6-
well plates (2 X 10
5
 cells in 2 ml medium) and incubated overnight. An equal volume of medium 
containing the appropriate drug or vehicle (final concentrations: 1 µM rapamycin, 10 nM everolimus, 
10 nM temsirolimus, 100 nM BEZ235, 50 nM AZD8055 or 0.1% DMSO) was then added [21]. Cells 
were harvested at 24 h (6-well plates: for GAS5 determination) or at 72 h (96-well plates: for MTS 
assay).   
 
Culture Proliferation assay 
Growth was assessed by a tetrazolium salt (MTS) assay or by direct microscopic counting. The MTS 
assay comprised CellTiter 96 Aqueous One Solution Cell Proliferation Assay, which was used in 
accordance to the manufacturer’s instructions and as previously described [10, 21]. Medium blanks 
containing the drugs under test were run with each assay and the absorbance readings at 490 nm 
(A490) were subtracted from the appropriate test readings. For direct microscopic counting, adherent 
cells were collected by trypsinisation, stained with 0.1% [w/v] nigrosin blue, and counted using a 
hemocytometer; cells that excluded the dye were considered to be viable. 
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Clonogenic Growth Assay 
Long-term survival of cells was determined by a colony forming assay. Cells were washed 48 h post 
drug treatment in sterile PBS and re-suspended in fresh medium supplemented with 10% cell-
conditioned medium (1 mL/cm
2
 culture area), and proportions (usually 2.5-10.0 µl cells) were plated 
into 6-well culture plates in 2.5 mL final culture volume. After 2-4 weeks, cells were stained with 
crystal violet (0.1% (w/v) in methanol) and the number of colonies (comprising ≥10 cells) were 
counted.  
 
Quantitative RT-PCR 
Total RNA was extracted from cells, as previously described [10, 25, 26]. RNA was DNAse treated 
prior to cDNA synthesis. cDNA was synthesized using 200 U of Moloney mouse leukaemia virus 
reverse transcriptase using Random hexame  Primer (Promega) according to the manufacturer’s 
instructions and as previously described [25, 27]. 
 
The primer sequences used for GAS5 quantification were: forward 5’-CCTGGACCAGCTTAATGGTT-3’ 
and reverse 5’-GTCTGCCTGCATTTCTTCAA-3’ (product size 190 bp). Briefly, reactions 12 µl final 
volume) contained 1X Brilliant SYBR green QPCR mastermix, 400 nmol  each of forward and reverse 
primers and 10 ng sample cDNA. All samples were analysed in triplicate [25, 26]. The target genes 
were normalised to endogenous controls GAPDH and or 18S rRNA, and relative quantification was 
carried out using the 2
-ΔΔCT
 method, where: -ΔΔCT = cycle threshold (CT), 
(GAS5 of cell line-GAPDH cell line)-(GAS5 of 
vehicle-GAPDH of vehicle)
. Data are expressed relative to vehicle treated controls. 
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Statistical Analyses 
All experiments were repeated at least three times with triplicate determinations in each set of 
experiments. Data are presented as the mean ± SEM; the number of observations (n) refers to 
number of different experiments, each derived from a separate culture. Data analysis was carried 
out by one-way ANOVA with Dunnett’s multiple comparison post-test or Bonferroni’s multiple 
comparison test using GraphPad Prism. 
 
Results 
Endogenous GAS5 expression 
A range of established, well characterized prostate cell lines were studied, comprising: PNT2C2, 
derived by immortalisation of normal prostate cells [31]; 22Rv1, an androgen-sensitive cell line 
derived from a prostate cancer xenograft [32]; LNCaP, an androgen-dependent cell line derived from 
a supraclavicular lymph node metastasis of prostate cancer [33]; PC-3, an androgen-independent cell 
line derived from a bone metastases of prostate cancer [34] and DU 145, an androgen independent 
cell line derived from a brain metastasis of prostate cancer [35]. 
 
Previous work has shown that GAS5 levels are reduced in prostate cancer cell lines representative of 
advanced disease, relative to immortalized prostate cells [22]. Indeed measurement of GAS5 lncRNA 
levels in actively growing cells in the present study confirmed these findings. Thus, relative to 
PNT2C2 cells, values were similar in 22Rv1 cells but markedly lower in LNCaP, DU 145 and PC-3 cells 
(Fig. 1). Among the latter group of cell lines, which are all derived from prostate metastases, levels 
were significantly lower in PC-3 cells compared with LNCaP cells, whereas DU 145 cells exhibited 
intermediate levels of expression (Fig. 1).  
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Rapamycin and rapalogues selectively modulate GAS5 expression and culture growth in prostate 
cell lines 
The effectiveness of mTOR inhibitors to enhance cellular GAS5 lncRNA levels in a range of prostate 
cell lines was examined, since GAS5 promotes the death of prostate cancer cells [10]. The first 
generation mTOR inhibitors rapamycin, everolimus and temsirolimus were chosen initially for this 
study [28-30]. 
 
In general, first generation mTOR inhibitors markedly enhanced GAS5 expression and slightly 
inhibited the growth of  PNT2C2 cells (Fig. 2A). In the prostate cancer cell lines, 22Rv1 (Fig. 2B ) and 
LNCaP (Fig. 2C ), cellular GAS5 levels were enhanced by all agents to a similar extent as for PNT2C2 
cells, but more potent inhibition of culture growth and clonogenic activity was seen. In contrast, PC-
3 and DU 145 cells, were characterized by resistance to all inhibitors, in terms of GAS5 cellular levels, 
short-term culture growth and clonogenic activity (Fig. 2D and 2E).  
 
Second generation mTOR inhibitors selectively modulate GAS5 expression and growth in prostate 
cell lines 
The mTOR inhibitors are in increasing clinical use, and resistance to such agents, especially first 
generation inhibitors which act selectively on mTORC1, is becoming progressively evident.  This has 
prompted the development of inhibitors with broader specificity, i.e the dual mTORC1/mTORC2 
inhibitor, AZD8055, and the combined PI3K/mTOR inhibitor, BEZ235. In related work, we have 
observed that these newer generation inhibitors can effectively enhance cellular GAS5 levels in 
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breast cancer cells which otherwise show resistance to selective mTORC1 inhibitors [21]. For these 
reasons, we examined the effects of such agents on prostate cell lines.   
 
However, the pattern of cell line response to both AZD8055 and BEZ235 was similar to that of the 
rapalogues, insofar as these two drugs elevated GAS5 expression and inhibited growth/clonogenic 
activity in PNT2C2 (Fig. 3A), 22Rv1 (Fig. 3B) and LNCaP cells (Fig. 3C) only, whereas the PC-3 and DU 
145 cell lines showed no increase in GAS5 levels accompanied by complete resistance to these 
agents (Fig. 3D and 3E). 
 
GAS5 silencing attenuates mTOR inhibitor action in prostate cancer cells. 
GAS5 lncRNA has been previously shown to be required for mTOR inhibitor action in a range of 
lymphoid cell lines [31], and a similar relationship may account for the reduced sensitivity of PC-3 
and DU 145 cells to mTOR inhibitors, particularly since GAS5 levels are low in these cell lines. To test 
the postulate that GAS5 lncRNA is required for mTOR inhibitor action in prostate cancer cells, we 
initially examined the effect of GAS5 silencing on mTOR inhibitor action in the two sensitive cell 
lines, 22Rv1 and LNCaP, which exhibit relatively high and low steady state levels of GAS5 lncRNA, 
respectively (Fig. 4 and 5).  Two different GAS5 siRNAs were employed in these experiments to 
reduce the likelihood of ‘off-target’ effects.  
 
In 22Rv1 cells, GAS5 transcript levels were reduced by ca. 80% in cells treated with each GAS5 siRNA 
(Fig. 4A). This was accompanied by a small (ca. 30%) reduction in culture growth (Fig. 4B). Rapalogue 
treatment produced the expected growth inhibition in mock-transfected cells (Fig. 4C) and in cells 
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transfected with negative control siRNA cells (Fig. 4D), whereas prior GAS5 silencing, markedly and 
consistently attenuated such growth inhibition (Figs. 4E and 4F).   
 
The two GAS5 siRNAs also markedly reduced GAS5 expression in LNCaP cells (Fig. 5A), albeit this was 
without any effect on culture growth (Fig. 5B). In agreement with findings in 22Rv1 cells, rapalogues 
markedly inhibited the growth of control LNCaP cells (Figs. 5C and 5D) but had little effect on cells in 
which GAS5 expression had been silenced (Figs. 5E and 5F). Taken together, these findings support 
the hypothesis that GAS5 lncRNA is required for the growth inhibitory activity of rapalogues in 
prostate cancer cells. 
 
GAS5 lncRNA sensitizes PC-3 and DU 145 cells to mTOR inhibitors 
We next examined if prior transfection with GAS5 lncRNA could influence the sensitivity of PC-3 and 
DU 145 cells to both first generation and second generation mTOR inhibitors (Figs. 6 and 7). 
Nucleofection of the GAS5 plasmid construct enhanced cellular GAS5 levels three-fold in both PC-3 
(Fig. 6A) and DU 145 cells (Fig. 7A) and this was without effect on the overall rate of culture growth 
(Figs. 6B and 7B). Both mock- and vector-transfected controls exhibited complete insensitivity to all 
mTOR inhibitors in terms of their culture growth (Figs. 6C, 6D, 7C and 7D), as expected, whereas cells 
transfected with the GAS5 lncRNA exhibited marked inhibition of culture growth upon rapalogue 
treatment (Figs. 6E and 7E).  These findings therefore suggest that a minimum level of GAS5 lncRNA 
is required for the cytostatic/cytotoxic action of mTOR inhibitors on prostate cancer cells. 
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Discussion 
 
A major problem with current, first line androgen deprivation therapy for prostate cancer is the 
development of CRPC, which ultimately proves lethal [28]. Thus there is an urgent need to develop 
new therapies for CRPC and GAS5 lncRNA may offer new opportunities in this regard, since the 
survival of prostate cancer cells upon challenge with chemotherapeutic agents and other inducers of 
apoptosis has been shown to inversely correlate with cellular GAS5 lncRNA levels [10]. Here we have 
investigated mTOR inhibition as a strategy to enhance GAS5 levels in prostate cancer cells, and we 
demonstrate that such agents are effective in androgen-dependent/sensitive cell lines (22Rv1 and 
LNCaP) but not in androgen-independent cell lines (PC-3 and DU 145). The latter cells are 
characterized by relatively low levels of endogenous GAS5 lncRNA, and we further demonstrate that 
GAS5 lncRNA is itself required for mTOR inhibitor action in prostate cancer cells, thereby providing 
an explanation for the resistance of androgen-independent cells to mTOR inhibition. Moreover, 
these findings have important implications for prostate cancer therapies involving mTOR inhibitors.  
 
Currently there is much interest in the use of mTOR inhibitors as novel therapies in prostate cancer, 
and mTOR inhibitors would therefore appear an attractive pharmacological option to enhance 
cellular GAS5 lncRNA levels [16, 32]. First and second generation mTOR inhibitors exerted robust 
effects on both androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) prostate cancer cell 
lines, whereas androgen-independent PC-3 and DU 145 cells failed to respond to these agents (at 
the concentrations studied here), both in terms of GAS5 expression and culture growth. Similar 
findings have been reported for breast cancer cell lines, insofar as growth and GAS5 expression in 
hormone-independent cells show greater resistance to mTORC1 and combined mTORC1/mTORC2 
inhibition than hormone-sensitive cells [21]. Thus using mTOR inhibitors to  elevate GAS5 levels in 
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prostate cancer cells in order to promote their death  is unlikely to succeed in CRPC, but it may be 
successful in less advanced disease.  Alternative approaches are therefore required to elevate GAS5 
expression levels in CRPC. 
 
Studies in lymphoid cells have shown that GAS5 lncRNA is required for rapalogue action, but this 
issue has not been previously addressed in prostate cells or any other epithelial cell type [20]. Since 
endogenous GAS5 lncRNA levels are shown to be lower in prostate cancer cell lines derived from 
metastases than in immortalized prostate cells, in confirmation of previous findings [[22], we 
postulated that a similar relationship may account for mTOR sensitivity in prostate cells. Here we 
demonstrate that prior GAS5 silencing induces mTOR inhibitor-insensitivity (both in terms of GAS5 
lncRNA expression and culture growth) in the otherwise mTOR-sensitive cell lines, 22Rv1 and LNCaP, 
thereby demonstrating a requirement for GAS5 lncRNA for rapalogue action. Moreover, upon 
transfection with GAS5 lncRNA, PC-3 and DU 145 cells acquire rapalogue sensitivity, further 
demonstrating that GAS5 lncRNA modulates mTOR inhibitor action.  Thus decreased GAS5 
expression in prostate cancer cells, such as occurs upon the acquisition of castrate-resistance, not 
only has the potential to attenuate the action of classical chemotherapeutic drugs [10], but also that 
of more novel targeted therapies, such as mTOR inhibitors. Better understanding of the mechanisms 
underlying reduced expression of GAS5 lncRNA upon the acquisition of castrate resistance is 
required, as this will help identify potential alternative means to enhance cellular GAS5 expression. 
Currently we are investigating epigenetic mechanisms in this respect, as well as the involvement of 
the recently discovered  GAS5 antisense RNA 1 (GAS5-AS1) gene.   
 
Current findings have broader implications for the use of mTOR inhibitors in prostate cancer. The 
oncogenic PI3K/Akt/mTOR signalling pathway plays a key role in the development and maintenance 
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of prostate cancer and is deregulated in the majority of advanced prostate cancers [20]. In 
particular, the pathway serves as a critical nexus for the integration of growth signals with 
downstream cellular processes so that its activation such as occurs in prostate cancer [7-9] provides 
mechanisms for cancer cells to overcome the stress associated with, for example, androgen 
deprivation [5, 33]. These considerations have prompted the active investigation of mTOR inhibitors, 
either as single agents or in combination with other agents, as a novel targeted therapy for advanced 
prostate cancer, and the clinical effectiveness of single agent, first-generation mTOR inhibitors, such 
as everolimus and temsirolimus, has so far been disappointing.  Our data, demonstrating an 
association between low GAS5 levels and increased resistance to the growth inhibitory effects of 
rapalogues in a model of androgen-independent disease, coupled with the direct demonstration that 
GAS5 lncRNA modulates mTOR inhibitor action in advanced prostate cancer cells, raises the 
possibility that low GAS5 expression in advanced prostate cancer may contribute to the clinical 
ineffectiveness of rapalogues in this disease. Current findings may also have broader implications for 
the clinical use of mTOR inhibitor-based therapies in a wide range of other cancers, including head 
and neck squamous cell carcinoma [34], glioblastoma multiforme [35], renal clear cell carcinoma 
[36], bladder cancer [37], pancreatic cancer [38] and non-small cell lung cancer [39], all of which are 
characterised by deficient GAS5 expression.  
Conclusions 
Cellular GAS5 expression can be enhanced by the use of mTORC1/mTOR inhibitors in androgen-
dependent/sensitive prostate cancer cells but not in androgen-independent cells. The refractoriness 
of the latter cells may in part be due to their low levels of endogenous GAS5 lncRNA expression, 
since GAS5 lncRNA positively regulates mTOR inhibitor action. Additional approaches are therefore 
required to increase GAS5 lncRNA expression in advanced prostate cancers in order to promote the 
effectiveness of chemotherapeutic agents and ultimately to improve and enhance patient outcomes.  
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Figure Legends 
 
Figure 1. Endogenous levels of GAS5 lncRNA in prostate cell lines. Endogenous GAS5 lncRNA levels 
were determined in actively growing prostate cell lines by RT-qPCR. Data are expressed as a 
percentage relative to PNT2C2 cells using ΔCT analysis, using GAPDH for normalization. Each bar 
represents the mean ± SEM for three independent experiments. Data were analysed by one-way 
ANOVA with Bonferroni’s multiple comparison test. #, P < 0.001 vs PNT2C2, *, P < 0.001 vs 22Rv1, ^, 
P < 0.001 vs LNCaP, -, P < 0.05 vs DU 145. 
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Figure 2. Effects of pharmacological inhibitors of mTORC1 activity on GAS5 expression, culture 
growth and the survival of prostate cell lines.  Effects of rapamycin 1 µM (R), everolimus 10 nM (E) 
and temsirolimus 10 nM (T) on GAS5 expression (24h; left-hand panel), culture growth (72 h; middle 
panel) and clonogenic survival (right-hand panel) in: A PNT2C2 cells B 22Rv1 cells, C LNCaP cells, D 
PC-3 cells and E DU 145 cells. Results are expressed as a proportion of the respective vehicle-treated 
controls. Each bar represents the mean ± SEM from three independent experiments. Data were 
analysed by one-way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05; **, P < 0.01 
and ***,  P < 0.001 versus vehicle.  
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Figure 3. Effects of combined mTORC1/mTORC2 and dual mTOR/PI3K inhibitors on GAS5 
expression, culture growth and the survival of prostate cell lines.  Effects of AZD8055 (50 nM) and 
BEZ235 (100 nM) on GAS5 expression (24h; left-hand panel), culture growth (72h; middle panel) and 
clonogenic survival (right-hand panel) in: A PNT2C2 cells, B 22Rv1 cells, C LNCaP cells, D PC-3 cells 
and E DU 145 Cells. Results are expressed as a proportion of the respective vehicle-treated controls. 
Each bar represents the mean ± SEM from three independent experiments. Data were analysed by 
one-way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05; **, P < 0.01 and ***,  P < 
0.001 versus vehicle.  
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Figure 4. Effect of GAS5 silencing on mTOR inhibitor action in 22Rv1 cells. 22Rv1 cells were 
transfected with the indicated GAS5 siRNA (GAS5#3 or GAS5#4), negative control (NC) siRNA or 
mock-transfected and, after 48 h, samples were collected for determination of GAS5 lncRNA levels 
and cells were exposed to rapalogues (rapamycin 1 µM (R), everolimus 10 nM (E) and temsirolimus 
10 nM (T)) for 72 h. A GAS5 lncRNA levels; data are expressed relative to  mock-transfected cells. B 
MTS assay results comparing the absolute growth of vehicle-treated, transfected cells. C-F MTS assay 
of the effect of rapalogues on the growth of transfected cells; data are expressed relative to 
respective vehicle (V)-treated controls for: C mock-transfected cells, D NC transfected cells, E 
GAS5#3 transfected cells and F GAS5#4 transfected cells. Each bar represents the mean value ± SEM 
from three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. *, P < 0.05 and ***, P < 0.001 versus the respective 
vehicle-treated control. 
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Figure 5. Effect of GAS5 silencing on mTOR inhibitor action in LNCaP cells.  
LNCaP cells were transfected with the indicated GAS5 siRNA (GAS5#3 or GAS5#4), negative control 
(NC) siRNA or mock-transfected and, after 48 h, samples were collected for determination of GAS5 
lncRNA levels and cells were exposed to rapalogues (rapamycin 1 µM (R), everolimus 10 nM (E) and 
temsirolimus 10 nM (T)) for 72 h. A GAS5 lncRNA levels; data are expressed relative to mock-
transfected cells. B MTS assay results comparing the absolute growth of vehicle-treated, transfected 
cells. C-F MTS assay of the effect of rapalogues on the growth of transfected cells; data are 
expressed relative to respective vehicle (V)-treated controls for: C mock-transfected cells, D NC 
transfected cells, E GAS5#3 transfected cells and F GAS5#4 transfected cells. Each bar represents the 
mean value ± SEM from three independent experiments. Data were analysed for significance by one-
way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05 and ***, P < 0.001 versus the 
respective vehicle-treated control. 
 
Page 50 of 59
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
The Prostate
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Figure 6. Effect of GAS5 lncRNA on mTOR inhibitor action in PC-3 cells.  
PC-3 cells were transfected with plasmids corresponding to mature lncRNA (pcDNA3+GAS5) or 
empty vector (pcDNA3), or mock-transfected. At 24 h, samples were taken for determination of 
GAS5 lncRNA levels, and cells were treated with mTOR inhibitors (rapamycin [1 µM; R]; everolimus 
[10 nM; E]; temsirolimus [10 nM; T]; AZD8055 [50 nM; AZD]; and BEZ235 [100 nM; BEZ]) for 72h. A 
GAS5 lncRNA levels; data are relative to mock-transfected cells. B MTS assay results comparing the 
absolute growth of vehicle-treated, transfected cells only. C-E MTS assay results for mTOR inhibitor-
treated cells; data are expressed relative to vehicle-treated cells for: C mock-transfected cells, D 
vector-transfected cells, E GAS5 lncRNA-transfected cells. Each bar represents the mean value ± SEM 
from three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. ***, P < 0.001 versus vehicle control. 
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Figure 7. Effect of GAS5 lncRNA on mTOR inhibitor action in DU 145 cells. DU 145 cells were 
transfected with plasmids corresponding to mature lncRNA (pcDNA3+GAS5) or empty vector 
(pcDNA3), or mock-transfected. At 24 h, samples were taken for determination of GAS5 lncRNA 
levels, and cells were treated with mTOR inhibitors (rapamycin [1 µM; R]; everolimus [10 nM; E]; 
temsirolimus [10 nM; T]; AZD8055 [50 nM; AZD]; and BEZ235 [100 nM; BEZ]) for 72h. A GAS5 lncRNA 
levels; data are relative to mock-transfected cells. B MTS assay results comparing the absolute 
growth of vehicle-treated, transfected cells only. C-E MTS assay results for mTOR inhibitor-treated 
cells; data are expressed relative to vehicle-treated cells for: C mock-transfected cells, D vector-
transfected cells, E GAS5 lncRNA-transfected cells. Each bar represents the mean value ± SEM from 
three independent experiments. Data were analysed for significance by one-way ANOVA with 
Dunnett’s multiple comparison post-test. . ***, P < 0.001 versus vehicle control. 
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